Ivabradine Sandoz

Ivabradine, the active ingredient in Ivabradine Sandoz, is an If channel inhibitor presented as an oral tablet. By selectively slowing the sinus node, it reduces heart rate without affecting contractility, making it useful for managing chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels.

Ivabradine is used to manage conditions where heart‑rate reduction improves outcomes, particularly in the angina and heart‑failure therapeutic areas. - Chronic stable angina: decreases the frequency of angina episodes by lowering heart rate. - Heart failure with reduced ejection fraction: improves symptoms and may reduce hospitalisation by controlling heart rate. - Patients intolerant to beta‑blockers: offers heart‑rate reduction without beta‑adrenergic blockade, providing an alternative therapeutic option.

Ivabradine may be associated with several adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: excessive slowing of heart rate. - Headache. - Dizziness.

Serious or Rare Side Effects: - Atrial fibrillation: new‑onset irregular rhythm. - Severe hypotension: marked drop in blood pressure. - Vision loss: persistent visual impairment.

When prescribing Ivabradine, clinicians should consider several safety and handling precautions. - Indication confirmation: ensure patient has chronic stable angina or HFrEF and is in sinus rhythm. - Heart‑rate monitoring: check resting heart rate before initiation and periodically thereafter. - Concomitant beta‑blocker use: avoid excessive heart‑rate reduction when combined with beta‑blockers. - Liver function: adjust use in patients with moderate hepatic impairment. - Pregnancy and lactation: avoid use as safety data are insufficient. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Ivabradine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Ivabradine plasma levels, raising risk of bradycardia. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness by lowering drug concentrations. - Concomitant use with other heart‑rate lowering agents (e.g., digoxin, verapamil): can cause excessive bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment and close monitoring. - Antihypertensive agents: additive blood pressure effects should be observed. - QT‑prolonging drugs: monitor ECG as combined effect may affect cardiac conduction.